Form 4: Arcutis Director Halley Gilbert Receives Equity Grant

Director Halley E. Gilbert was granted 5,778 restricted stock units and 16,667 stock options as part of annual director compensation.

Summary

• Director Halley E. Gilbert received an equity grant from Arcutis Biotherapeutics, Inc. on June 5, 2026.
• The grant consisted of 5,778 Restricted Stock Units (RSUs) and 16,667 stock options.
• The stock options have an exercise price of $21.23 per share.
• Both the RSUs and the stock options are scheduled to vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The grant results in minor dilution to existing shareholders.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The equity grants are subject to standard vesting schedules tied to continued service as a director through the 2027 annual meeting cycle.

Industry Context

StockSavvy.ai notes that standard annual equity grants for non-employee directors are a routine corporate governance practice in the biotechnology sector to ensure board retention and alignment.

Comparison to Industry Standards

• The grant structure is consistent with standard compensation packages for independent directors in mid-cap biopharmaceutical companies.
• Vesting periods of one year are standard practice for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs and options on the earlier of June 5, 2027, or the 2027 annual meeting of stockholders.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Director Compensation, Equity Grant